Saumbon, Arabella .
HRN: 27-13-78 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/25/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/25/2025
05/31/2025
IV
700 Mg
Q6H
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes